All Stories

  1. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, October 2019, Taylor & Francis

    Dr Jiaxing Huang

  2. C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence

    Article • Journal of Investigative Surgery, March 2019, Taylor & Francis

    Dr Jiaxing Huang, Jian Li

  3. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial

    Article • Cancer Management and Research, October 2018, Dove Medical Press

    Dr Jiaxing Huang

  4. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer

    Article • OncoTargets and Therapy, September 2016, Dove Medical Press

    Dr Jiaxing Huang